PD-1/PD-L1 blockade in HIV-associated advanced lung cancer: from mechanisms to clinical practice
Authors:
- Ruifang ChenRCRuifang Chen
- Shuai RenSRShuai Ren
- Haicheng TangHTHaicheng Tang
- Qingguo WuQWQingguo Wu
Open Access
- 10 February 2026
- journal article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17
Abstract
The advent of antiretroviral therapy (ART) has ushered in a remarkable era of prolonged survival for individuals living with Human Immunodeficiency Virus (HIV). Yet this prolonged survival has paradoxically coincided with an increasing burden of non-AIDS-defining malignancies, particularly advanced non-small cell lung cancer. Targeted inhibitors of the programmed cell death protein-1 (PD-1) pathway and its ligand, programmed death-ligand 1 (PD-L1), have now become the cornerstone of modern immunotherapy. Nevertheless, comprehensive studies evaluating the application of these inhibitors in HIV-positive individuals with concurrent lung cancer remain scarce. This review elucidates the dual mechanism of action of PD-1/PD-L1 inhibitors in this patient population: on one hand, blockade of the PD-1/PD-L1 axis enhances anti-tumor activity in vivo , while on the other, it reverses latent HIV infection and restores immune function. Current evidence suggests that PD-1/PD-L1 inhibitors demonstrate favorable safety and promising efficacy in ART-controlled HIV patients with lung cancer. However, comprehensive clinical trials remain imperative to validate their long-term outcomes, given the existing limitations of small sample sizes and population heterogeneity in current studies. This article seeks to establish a theoretical foundation for tailoring immunotherapy strategies to this unique patient population.Keywords
This publication has 94 references indexed in Scilit:
- Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non–Small Cell Lung CancerJAMA Oncology, 2025
- PD-1/PD-L1 axis: implications in immune regulation, cancer progression, and translational applicationsJournal of Molecular Medicine, 2024
- HIV Associated Lung Cancer: Unique Clinicopathologic Features and Immune Biomarkers Impacting Lung Cancer Screening and ManagementClinical Lung Cancer, 2023
- Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and CancerCurrent HIV/AIDS Reports, 2020
- Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 InfectionJAMA Oncology, 2020
- PD‐1 inhibitors for non‐small cell lung cancer patients with special issues: Real‐world evidenceCancer Medicine, 2020
- Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer—A Phase 1 StudyJAMA Oncology, 2019
- Clinical outcomes of African American patients with advanced or metastatic non-small cell lung cancer on Nivolumab in a single community-based cancer centerMedical Oncology, 2018
- High PD-L1 expression indicates poor prognosis of HIV-infected patients with non-small cell lung cancerCancer Immunology, Immunotherapy, 2017
- Immune checkpoints and their inhibition in cancer and infectious diseasesEuropean Journal of Immunology, 2017